References
1. Davies L, Ouellette M, Hunter M, Welch HG. The increasing incidence of small thyroid cancers: where are the cases coming from? Laryngoscope. 2010 Dec;120(12):2446–2451.
2. Ito Y, Miyauchi A, Oda H. Low-risk papillary microcarcinoma of the thyroid: A review of active surveillance trials. Eur J Surg Oncol. 2018;44(3):307–315.
3. Ito Y, Miyauchi A, Inoue H, Fukushima M, Kihara M, Higashiyama T, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg. 2010 Jan;34(1):28–35.
4. Sugitani I, Ito Y, Miyauchi A, Imai T, Suzuki S. Active Surveillance Versus Immediate Surgery: Questionnaire Survey on the Current Treatment Strategy for Adult Patients with Low-Risk Papillary Thyroid Microcarcinoma in Japan. Thyroid. 2019 Sep 25;29(11):1563–1571.
5. Sakai T, Sugitani I, Ebina A, Fukuoka O, Toda K, Mitani H, et al. Active surveillance for t1bn0m0 papillary thyroid carcinoma. Thyroid. 2019 Jan 8;29(1):59–63.
6. Pacini F. Observation for newly diagnosed micro-papillary thyroid cancer: is now the time? J Endocrinol Invest. 2015 Jan;38(1):101–102.
7. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1–133.
8. Lee WK, Lee J, Kim H, Lee SG, Choi SH, Jeong S, et al. Peripheral location and infiltrative margin predict invasive features of papillary thyroid microcarcinoma. Eur J Endocrinol. 2019 Aug;181(2):139–149.
9. Chen Y, Sadow PM, Suh H, Lee KE, Choi JY, Suh YJ, et al. BRAF(V600E) Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta-Analysis. Thyroid. 2016 Feb;26(2):248–255.
10. Kim KJ, Kim SG, Tan J, Shen X, Viola D, Elisei R, et al. BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. Eur J Cancer. 2020;124:161–169.
11. Lin K-L, Wang O-C, Zhang X-H, Dai X-X, Hu X-Q, Qu J-M. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol. 2010 Dec;17(12):3294–3300.
12. Niemeier LA, Kuffner Akatsu H, Song C, Carty SE, Hodak SP, Yip L, et al. A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer. 2012 Apr 15;118(8):2069–2077.
13. Zheng X, Wei S, Han Y, Li Y, Yu Y, Yun X, et al. Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases. Ann Surg Oncol. 2013 Jul;20(7):2266–2273.
14. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007 Sep;246(3):375–81; discussion 381.
15. Centers for Disease Control and Prevention. National Vital Statistics Reports, Volume 69 (12) [Internet]. [cited 2020 Nov 1]. Available from: https://www.cdc.gov/nchs/products/index.htm
16. Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014 Jan;24(1):27–34.
17. Lang BH-H, Wong CKH. A cost-effectiveness comparison between early surgery and non-surgical approach for incidental papillary thyroid microcarcinoma. Eur J Endocrinol. 2015 Sep;173(3):367–375.
18. Sugitani I, Ito Y, Takeuchi D, Nakayama H, Masaki C, Shindo H, et al. Indications and Strategy for Active Surveillance of Adult Low-Risk Papillary Thyroid Microcarcinoma: Consensus Statements from the Japan Association of Endocrine Surgery Task Force on Management for Papillary Thyroid Microcarcinoma. Thyroid. 2020 Nov 2;
19. Brito JP, Ito Y, Miyauchi A, Tuttle RM. A clinical framework to facilitate risk stratification when considering an active surveillance alternative to immediate biopsy and surgery in papillary microcarcinoma. Thyroid. 2016 Jan;26(1):144–149.
20. Kimura E, Nikiforova M, Zhu Z, Knauf J, Nikiforov Y, Fagin J. High Prevalence of BRAF Mutations in Thyroid Cancer: Genetic Evidence for Constitutive Activation of the RET/PTC-RAS-BRAF Signaling Pathway in Papillary Thyroid Carcinoma1.
21. Sturgis EM, Sherman SI. Should papillary thyroid carcinoma be observed?: a word of caution. Arch Otolaryngol Head Neck Surg. 2010 May;136(5):444–446.
22. Pitt SC, Saucke MC, Roman BR, Alexander SC, Voils CI. The Influence of Emotions on Treatment Decisions About Low-Risk Thyroid Cancer: A Qualitative Study. Thyroid. 2021 Nov 26;
23. Haymart MR, Miller DC, Hawley ST. Active Surveillance for Low-Risk Cancers - A Viable Solution to Overtreatment? N Engl J Med. 2017 Jul 20;377(3):203–206.
24. Venkatesh S, Pasternak JD, Beninato T, Drake FT, Kluijfhout WP, Liu C, et al. Cost-effectiveness of active surveillance versus hemithyroidectomy for micropapillary thyroid cancer. Surgery. 2017;161(1):116–126.